ICB

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
Patient, ICB, Neoplasm, Cancer, Ubiquitin, Biology, AACR, Phenotype, Aberrant, MAVS, Autoimmune disease, PD-1, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy. These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.

Key Points: 
  • These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
  • Our efforts in helping to define the underlying biology of acquired resistance were recently revealed with a publication in Cancer Cell,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • TRIM7 also contributes to PD-1 acquired resistance through ubiquitination and degradation of STING and MAVS.
  • A copy of the AACR presentation will be available on the Investors section of the Company’s website shortly after the event.

UNCF Institute for Capacity Building Announces Recipients of 2023-2024 Faculty Research Mini-Grant Programs

Retrieved on: 
Monday, April 8, 2024
Faculty, University, Benedict College, ICB, Oakwood University, UNCF, Burden, Research, Food, Policy, Entrepreneurship, Capacity building, Student, Elizabeth City State University, Capacity, HBCU, Publication, Ecosystem, Curriculum, Intellectual property, International Patient Safety Goals, Lightcast, Nursing

ATLANTA, G.A., April 08, 2024 (GLOBE NEWSWIRE) -- UNCF’s (United Negro College Fund) Institute for Capacity Building (ICB) is pleased to announce the recipients of the 2023-2024 Faculty Research Mini-Grant programs, sponsored by Kroger, Lightcast and Michelson Institute for Intellectual Property.

Key Points: 
  • ATLANTA, G.A., April 08, 2024 (GLOBE NEWSWIRE) -- UNCF’s (United Negro College Fund) Institute for Capacity Building (ICB) is pleased to announce the recipients of the 2023-2024 Faculty Research Mini-Grant programs, sponsored by Kroger, Lightcast and Michelson Institute for Intellectual Property.
  • These mini-grant opportunities were presented at the UNCF UNITE 2023 conference, marking a significant step towards fostering faculty research, professional development and strategic partnerships.
  • This investment by Kroger/UNCF will support research and capacity building efforts to investigate its root causes and propose interventions.
  • If you are interested in sponsoring a faculty research mini-grant for the 2024-2025 program, go to UNCFunite.org .

 Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Toxicity, Netherlands Cancer Institute, VLS, Therapeutic index, Cell, Patient, ICB, Neoplasm, Immunology, Hypertelorism, Cancer, Infection, Publication, Immunity, IL-2, NKI, CD8, Immune system, Division, NK, Autoimmunity, PD-1, Vaccine

The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.

Key Points: 
  • The papers were authored by Asher Bio scientists and collaborators at The Netherlands Cancer Institute (NKI), respectively, and published online in Cancer Discovery on April 2, 2024.
  • “These co-published manuscripts are the culmination of several years of great collaboration between Asher Bio scientists and our academic co-founders, Dr.
  • Asher Bio systematically evaluated the properties needed for effective cis-targeting to CD8+ T cells and generated AB248, a CD8+ T cell selective IL-2.
  • To evaluate this hypothesis, Asher Bio’s collaborators at the NKI performed a comprehensive analysis of T cell reinvigoration following treatment with AB248.

Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GPCR, Gene, Immunotherapy, Patient, Immunosuppression, PAR2, ICB, Research, Tumor microenvironment, Cancer, G protein-coupled receptor, IND, AACR, Gq alpha subunit, Therapy, Drug resistance, Module (mathematics)

PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.

Key Points: 
  • PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.
  • Its upregulation across a variety of cancer types and expression on diverse cells within the tumor microenvironment underscore PAR2’s critical role in cancer development.
  • Remarkably, when compared to its most advanced competitors positioned in other therapeutic areas, this candidate has demonstrated clear differentiated features.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, commented: “We are excited to present our newest findings on DT-9045 at AACR.

All Metals Fabricating Celebrates 70 Years of Excellence

Retrieved on: 
Wednesday, January 24, 2024
Culture, Workforce, Family, AMF, Automation, ICB, AI, Metal, Interview, Robotics, Management

DALLAS, Jan. 24, 2024 /PRNewswire/ -- All Metals Fabricating, a leading force in the metal fabricating industry, marked a significant milestone with its 70th anniversary, commemorating a legacy of innovation and dedication to its valued workforce and clientele.

Key Points: 
  • DALLAS, Jan. 24, 2024 /PRNewswire/ -- All Metals Fabricating , a leading force in the metal fabricating industry, marked a significant milestone with its 70th anniversary, commemorating a legacy of innovation and dedication to its valued workforce and clientele.
  • AMF has set sail on a transformative expansion, initiating phase one of a groundbreaking $7 million automation plan.
  • In 1953, AMF opened as a sheet metal shop with a handful of capabilities.
  • Remarkably, the company has retained customers since the purchase, 45 years ago, showcasing a testament to its longstanding relationships and exceptional service .

UNCF Institute for Capacity Building Awarded 2023 Amazon Web Services IMAGINE Grant to Develop HBCUv

Retrieved on: 
Tuesday, December 19, 2023
Capacity building, AWS, UNCF, Student, Amazon, Capacity, ICB, Global health, Organization, Amazon Web Services, Management

ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- UNCF (United Negro College Fund) Institute for Capacity Building (ICB) is proud to announce that it has been awarded the 2023 Amazon Web Services (AWS) IMAGINE Grant.

Key Points: 
  • ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- UNCF (United Negro College Fund) Institute for Capacity Building (ICB) is proud to announce that it has been awarded the 2023 Amazon Web Services (AWS) IMAGINE Grant.
  • UNCF's HBCUv™ project, recognized in the Go Further, Faster category, stands out as a highly innovative endeavor that utilizes advanced cloud services.
  • "Receiving the 2023 AWS IMAGINE Grant is a significant achievement for UNCF.
  • Since the launch of the IMAGINE Grant Program in 2018, AWS has awarded over $7 million in unrestricted funds, AWS Promotional Credits, and AWS training support to 90 non-profit organizations.

Savara Added to the NASDAQ Biotechnology Index

Retrieved on: 
Wednesday, December 20, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, ICB, NASDAQ Biotechnology Index, Industry Classification Benchmark, NBI, Inc.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023.
  • The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
  • The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
  • Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Georgetown University, Tumor-associated macrophage, AMES, Research, GLP, Safety, Therapy, Incidence, RECIST, Toxicology, IND, Risk, Macrophage, Patient, FIH, PFS, MD Anderson Cancer Center, U.S. FDA, FDA, Pembrolizumab, Animal, ICB, SAB, Pharmacokinetics, Marketing, Investigational New Drug, FAAAS, Progression-free survival, ORR, MD, Cancer, MTD, Phase, Doctor of Philosophy, HDAC6, Biomarker, Infrared spectroscopy correlation table, Immunotherapy, Coronavirus Scientific Advisory Board, Neoplasm, Rat, Dog, Government, Pharmaceutical industry, Medicine

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.

Key Points: 
  • AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
  • "The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
  • "FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
  • Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."

Automotive Wiring Harness Market to Surpass US$ 96.0 Million by 2030 - Coherent Market Insights

Retrieved on: 
Monday, November 27, 2023
BDU, Metallic, Safety, Yura Corporation d.o.o., Maserati, China Internet Information Center, EVS, Aptiv, General Motors, Propulsion, Connector, ICB, Leoni AG, Yazaki, Analysis, Component, Republic, Growth, ADAS, Minda, BorgWarner, Lear Corporation, Renewable energy, Electric motor, Lamborghini

BURLINGAME, Calif., Nov. 27, 2023 /PRNewswire/ --  According to Coherent Market Insights, Global Automotive Wiring Harness market size was valued at US$ 53.58 Million in 2022 and is expected to surpass US$ 96.0 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030.

Key Points: 
  • BURLINGAME, Calif., Nov. 27, 2023 /PRNewswire/ --  According to Coherent Market Insights, Global Automotive Wiring Harness market size was valued at US$ 53.58 Million in 2022 and is expected to surpass US$ 96.0 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030.
  • The global automotive wiring harness market is experiencing strong growth owing to rising vehicle production, growing demand for electric vehicle, advancement in vehicle technology, and integration of advanced driver assistance system.
  • Key Trends and Analysis of the Global Automotive Wiring Harness Market:
    Growing integration of electronic devices into vehicles will drive the demand for automotive wiring harness market during the forecast period.
  • Moreover, employing safety features in automotive cars enhances the security of passengers in the vehicle, which has positively impacted the growth of the automotive wiring harness market.

Automotive Wiring Harness Market to Surpass US$ 96.0 Million by 2030 - Coherent Market Insights

Retrieved on: 
Monday, November 27, 2023
BDU, Metallic, Safety, Yura Corporation d.o.o., Maserati, China Internet Information Center, EVS, Aptiv, General Motors, Propulsion, Connector, ICB, Leoni AG, Yazaki, Analysis, Component, Republic, Growth, ADAS, Minda, BorgWarner, Lear Corporation, Renewable energy, Electric motor, Lamborghini

BURLINGAME, Calif., Nov. 27, 2023 /PRNewswire/ --  According to Coherent Market Insights, Global Automotive Wiring Harness market size was valued at US$ 53.58 Million in 2022 and is expected to surpass US$ 96.0 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030.

Key Points: 
  • BURLINGAME, Calif., Nov. 27, 2023 /PRNewswire/ --  According to Coherent Market Insights, Global Automotive Wiring Harness market size was valued at US$ 53.58 Million in 2022 and is expected to surpass US$ 96.0 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 7.7% from 2023 to 2030.
  • The global automotive wiring harness market is experiencing strong growth owing to rising vehicle production, growing demand for electric vehicle, advancement in vehicle technology, and integration of advanced driver assistance system.
  • Key Trends and Analysis of the Global Automotive Wiring Harness Market:
    Growing integration of electronic devices into vehicles will drive the demand for automotive wiring harness market during the forecast period.
  • Moreover, employing safety features in automotive cars enhances the security of passengers in the vehicle, which has positively impacted the growth of the automotive wiring harness market.